![Benoit Chéron](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Benoit Chéron
Director of Finance/CFO at IDI Emerging Markets SA
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christophe Thurieau | M | - |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 4 years |
Karin Garre | M | 67 |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 6 years |
Christian Peugeot | M | 70 |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | - |
Claude Bertrand | M | 62 |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
Abderahmane Fodil | M | 50 |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | 5 years |
Peter Bieliczky | M | - |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | 16 years |
Julien Kinic | M | - |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | 16 years |
Yann Malka | M | - |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | 23 years |
Elyes Bahri | M | - |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | 10 years |
Frances Wang | F | - |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | 8 years |
Soraya Salhi | F | - |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | 7 years |
Pascal Lemaire | M | - |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
François Thomazeau | M | 75 |
IDI Emerging Markets SA
![]() IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | - |
Statistics
Country | Connections | % of total |
---|---|---|
France | 9 | 69.23% |
Denmark | 4 | 30.77% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Benoit Chéron
- Personal Network